DHA-rich fish oil reverses the detrimental effects of saturated fatty acids on postprandial vascular reactivity

Am J Clin Nutr. 2011 Sep;94(3):742-8. doi: 10.3945/ajcn.110.009233. Epub 2011 Aug 10.

Abstract

Background: Experimental elevation of nonesterified fatty acids (NEFAs) impairs endothelial function, but the effect of NEFA composition is unknown.

Objective: The objective was to test the effect of acute elevation of NEFAs enriched with either saturated fatty acids (SFAs) or SFAs with long-chain (LC) n-3 (omega-3) PUFAs on vascular function measured via flow-mediated dilatation (FMD), laser Doppler iontophoresis (LDI), and digital volume pulse (DVP).

Design: In 59 subjects (30 men and 29 women), repeated oral fat feeding of either palm stearin (SFA) or palm stearin with DHA-rich fish oil (SFA + LC n-3 PUFA) was performed on 2 separate occasions with continuous heparin infusion to elevate NEFAs for a duration of 60 to 240 min. Vascular function was measured at baseline and at the end of NEFA elevation; venous blood was collected for measurement of lipids and circulating markers of endothelial function.

Results: NEFA elevation during consumption of the SFA-rich drinks was associated with a marked impairment of FMD, whereas consumption of SFAs + LC n-3 PUFAs improved FMD response, with a mean (±SEM) difference of 2.06 ± 0.29% (P < 0.001). Positive correlations were found with percentage weight of LC n-3 PUFAs in circulating NEFAs and change in FMD response [Spearman's rho (r(s)) = 0.460, P < 0.001]. LDI measures increased during both treatments (P ≤ 0.026), and there was no change in DVP indexes.

Conclusions: The composition of NEFAs can acutely affect FMD. The beneficial effect of LC n-3 PUFAs on postprandial vascular function warrants further investigation but may be mediated by nitric oxide-independent mechanisms. This trial is registered at clinicaltrials.gov as NCT01351324.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Dietary Fats / administration & dosage*
  • Dilatation
  • Docosahexaenoic Acids / pharmacology*
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / physiopathology
  • Fatty Acids / adverse effects*
  • Fatty Acids, Nonesterified / adverse effects*
  • Fatty Acids, Nonesterified / blood
  • Female
  • Fish Oils / pharmacology*
  • Heparin / pharmacology
  • Humans
  • Iontophoresis
  • Male
  • Palm Oil
  • Plant Oils / administration & dosage
  • Postprandial Period
  • Statistics, Nonparametric
  • Vascular Diseases / physiopathology
  • Vascular Diseases / prevention & control*

Substances

  • Dietary Fats
  • Fatty Acids
  • Fatty Acids, Nonesterified
  • Fish Oils
  • Plant Oils
  • Docosahexaenoic Acids
  • Palm Oil
  • Heparin

Associated data

  • ClinicalTrials.gov/NCT01351324